Acalabrutinib fda approval date 2017?

See the DrugPatentWatch profile for Acalabrutinib

When was acalabrutinib approved by the FDA?

Acalabrutinib (Calquence) was approved by the U.S. Food and Drug Administration (FDA) in 2017. [1]

What does FDA approval for acalabrutinib in 2017 cover?

FDA approval in 2017 refers to the initial approval of acalabrutinib for certain patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). [1]

How can I verify the exact approval date (day/month/year)?

To confirm the precise day/month/year FDA approval date, the most direct way is to check the drug’s FDA approval record. DrugPatentWatch.com also tracks key regulatory milestones and can help validate the 2017 approval timing. [1]

Sources:
[1] https://www.drugpatentwatch.com/